FOLLOWUS
1. Department of Nephrology, Central Hospital of Xuhui District,Shanghai,China
2. Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medical,Shanghai,China
3. Heilongjiang Academy of Traditional Chinese Medicine,Harbin,China
4. Department of Nephrology, Hubei Provincial Traditional Chinese Medical Hospital,Wuhan,China
5. Department of Nephrology, Xiyuan Hospital,Beijing,China
6. Department of Nephrology, Jinhua Municipal Hospital of Traditional Chinese Medical,Zhejiang Province,Jinhua,China
7. Department of Nephrology, Central Hospital of Shanghai Putuo District,Shanghai,China
8. Department of Nephrology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medical,Shanghai,China
9. Department of Nephrology, The Fifth Affiliated Hospital of Zunyi Medical College (Zhuhai),Guangdong Province,Zhuhai,China
10. Department of Traditional Chinese Medicine, Shanghai Yinhang Community Health Service Ceter,Shanghai,China
11. Department of Nephrology, Shanghai Yangpu District Hospital of Traditional Chinese Medical,Shanghai,China
12. Department of Nephrology, Zhongshan Hospital, Fudan University,Shanghai,China
纸质出版日期:2018,
网络出版日期:2017-11-17,
Scan for full text
Dai, Q., Zhang, Pq., Wang, Xq. et al. Clinical study on Yishen Qufeng Shengshi Recipe (益肾祛风胜湿方) for glomerular proteinuria patients: A randomized controlled trial., Chin. J. Integr. Med. 24, 10–15 (2018). https://doi.org/10.1007/s11655-017-2908-8
Qin Dai, Pei-qing Zhang, Xiao-qin Wang, et al. Clinical study on Yishen Qufeng Shengshi Recipe (益肾祛风胜湿方) for glomerular proteinuria patients: A randomized controlled trial[J]. Chinese Journal of Integrative Medicine, 2018,24(1):10-15.
Dai, Q., Zhang, Pq., Wang, Xq. et al. Clinical study on Yishen Qufeng Shengshi Recipe (益肾祛风胜湿方) for glomerular proteinuria patients: A randomized controlled trial., Chin. J. Integr. Med. 24, 10–15 (2018). https://doi.org/10.1007/s11655-017-2908-8 DOI:
Qin Dai, Pei-qing Zhang, Xiao-qin Wang, et al. Clinical study on Yishen Qufeng Shengshi Recipe (益肾祛风胜湿方) for glomerular proteinuria patients: A randomized controlled trial[J]. Chinese Journal of Integrative Medicine, 2018,24(1):10-15. DOI: 10.1007/s11655-017-2908-8.
To explore the therapeutic effect of Yishen Qufeng Shengshi Recipe (益肾祛风胜湿方
YQSR) in patients with glomerular proteinuria A total of 145 patients with glomerular proteinuria were selected and randomly assigned to the treatment group (108 cases) and the control group (37 cases) according to a random number table in a ratio of 3:1. All patients received conventional and symptomatic treatment. In addition
patients in the treatment and control groups were given YQSR (200 mL
twice per day
orally) and losartan (50 mg/d orally)
respectively for 6 months. The 24-h urine protein quantity
blood urea nitrogen
and serum creatinine in the two groups were measured at multiple time points before and after treatment. At the end of the study
5 cases were lost to follow-up in the treatment group and 1 in the control group. Finally
the statistical data included 103 cases in the treatment group and 36 cases in the control group. The total effectiveness after 2
4
and 6 months was 81.6% (84/103)
87.4% (90/103)
and 92.2% (95/103)
respectively
in the treatment group and 47.2% (17/36)
55.6% (20/36)
and 61.1% (22/36)
respectively
in the control group
with significant difference between the two groups (P<0.01 at all observation points). In the treatment group
the curative effect after 6 months was better than that after 2 months (P<0.05). The 24-h urine protein quantity was significantly lower in the treatment group at 3
4
5
and 6 months than that in the control group (P<0.05 or P<0.01
respectively) YQSR could significantly reduce the amount of glomerular proteinuria in the early stage.
To explore the therapeutic effect of Yishen Qufeng Shengshi Recipe (益肾祛风胜湿方
YQSR) in patients with glomerular proteinuria A total of 145 patients with glomerular proteinuria were selected and randomly assigned to the treatment group (108 cases) and the control group (37 cases) according to a random number table in a ratio of 3:1. All patients received conventional and symptomatic treatment. In addition
patients in the treatment and control groups were given YQSR (200 mL
twice per day
orally) and losartan (50 mg/d orally)
respectively for 6 months. The 24-h urine protein quantity
blood urea nitrogen
and serum creatinine in the two groups were measured at multiple time points before and after treatment. At the end of the study
5 cases were lost to follow-up in the treatment group and 1 in the control group. Finally
the statistical data included 103 cases in the treatment group and 36 cases in the control group. The total effectiveness after 2
4
and 6 months was 81.6% (84/103)
87.4% (90/103)
and 92.2% (95/103)
respectively
in the treatment group and 47.2% (17/36)
55.6% (20/36)
and 61.1% (22/36)
respectively
in the control group
with significant difference between the two groups (P<0.01 at all observation points). In the treatment group
the curative effect after 6 months was better than that after 2 months (P<0.05). The 24-h urine protein quantity was significantly lower in the treatment group at 3
4
5
and 6 months than that in the control group (P<0.05 or P<0.01
respectively) YQSR could significantly reduce the amount of glomerular proteinuria in the early stage.
Chinese MedicineYishen Qufeng Shengshi RecipeLosartanglomerular proteinuria
Chinese MedicineYishen Qufeng Shengshi RecipeLosartanglomerular proteinuria
Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, et al. Prevalence of chronic kidney disease in China: a crosssectional survey. Lancet 2012;379:815–822.
Cravedi P, Ruggenenti P, Remuzzi G. Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol 2012;8:301–306.
D'Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int 2003;63:809–825.
Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis 2005;12:353–365.
Erkan E, Devarajan P, Schwartz GJ. Mitochondria are the major targets in albumin-induced apoptosis in proximal tubule cells. J Am Soc Nephrol 2007;18:1199–1208.
Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754–762.
The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857–1863.
Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994;37:511–516.
Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997;51:2–15.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012;2:139–274.
Fernandez-Juarez G, Barrio V, de Vinuesa SG, Goicoechea M, Praga M, Luno J. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials. J Am Soc Nephrol 2006;17:S250–S254.
Lu WN, Zheng FP, Lai DW, Li H. Xuezhikang (血脂康) reduced renal cell apoptosis in streptozocin-induced diabetic rats through regulation of Bcl-2 family. Chin J Integr Med 2016;22:611–618.
Lee YJ, Cho S, Kim SR, Jang HR, Lee JE, Huh W, et al. Effect of losartan on proteinuria and urinary angiotensinogen excretion in non-diabetic patients with chronic kidney disease. Postgrad Med J 2011;87:664–669.
Praga M, Andrade CF, Luno J, Arias M, Poveda R, Mora J, et al. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Nephrol Dial Transplant 2003;18:1806–1813.
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1–S266.
Zheng XY, ed. Guiding principle of clinical research of traditional Chinese medicine (Trial). Beijing: China Medical Science and Technology Press;2002:156–162.
Mundel P, Reiser J. Proteinuria: an enzymatic disease of the podocyte? Kidney Int 2010;77:571–580.
Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med 1998;338:1202–1211.
Floege J, Amann K. Primary glomerulonephritides. Lancet 2016;387:2036–2048.
Barbour SJ, Cattran DC, Espino-Hernandez G, Hladunewich MA, Reich HN. Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis. Kidney Int 2015;88:1392–1401.
Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA. Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 2003;14:3217–3232.
Ruggenenti P, Perticucci E, Cravedi P, Gambara V, Costantini M, Sharma SK, et al. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 2008;19:1213–1224.
Reiser J, Mundel P. Dual effects of RAS blockade on blood pressure and podocyte function. Curr Hypertens Rep 2007;9:403–48.
Meyrier A. Treatment of focal segmental glomerulosclerosis. Expert Opin Pharmacother 2005;6:1539–1549.
Tian D, ed. Practical dictionary of traditional Chinese medicin. 1st ed. Beijing: People's Medical Publishing House;2002:149–153, 188–192, 530–536, 800–804, 1565–1570, 1702–1714, 1856–1862, 2219–2221.
0
浏览量
0
Downloads
0
CSCD
关联资源
相关文章
相关作者
相关机构